A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

Trial Details

NCT ID
NCT07538804
Phase
PHASE1 / PHASE2
Sponsor
Avistone Biotechnology Co., Ltd.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • ANS02
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Age ≥ 18 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
  • Life expectancy ≥ 12 weeks
  • Measurable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →